Abstract
The spread of coronavirus disease around the world has had an immense impact on most economic sectors. Yet amid the turmoil and chaos from the worldwide pandemic, one industry is thriving noticeably. The coronavirus disease is a once in a lifetime business opportunity for pharmaceutical companies. This study presents an artificial intelligence method composed of optimization and machine learning. Data envelopment analysis (DEA) is used to measure productivities and efficiencies of pharmaceutical companies during the COVID-19 pandemic using the additive model in window analysis, the BCC (Banker-Charnes-Cooper) model, and the CCR (Charnes-Cooper-Rhodes) model. The three models are assessed using DataStream financial information with research and development (R&D) investment. The results indicated the additive model's superiority in window analysis, followed by the BCC and CCR models. In the end, some of well-known data mining algorithms, based on the suggested data, have been evaluated in various tools to find the most efficient tool and algorithm.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
